Top Suppliers:I want be here

61622-34-2

61622-34-2 structure
61622-34-2 structure
  • Name: Cefotiam
  • Chemical Name: cefotiam
  • CAS Number: 61622-34-2
  • Molecular Formula: C18H23N9O4S3
  • Molecular Weight: 525.628
  • Catalog: API Antibiotics Cephalosporin
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2024-01-02 17:36:49
  • Cefotiam is a parenteral second-generation cephalosporin antibiotic. Cefotiam has broad-spectrum activity against gram-positive and gram-negative bacterias .Cefotiam has effective in preventing infection following a wide range of urologic surgeries[1][2][3].

Name cefotiam
Synonyms 7-[2-(2-aminothiazol-4-yl)acetamido]-3-[1-(2-N,N-dimethylaminoethyl)-tetrazol-5-yl]thiomethyl-3-cephem-4-carboxylic acid
MFCD00865087
CEFOTIAM HYDROCHLORIDE
Cefotiam (INN)
(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Haloapor
(6R)-7t-[2-(2-amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Ceradolan
Cefotiamum [INN-Latin]
Ceradon
Cefotiamum
Description Cefotiam is a parenteral second-generation cephalosporin antibiotic. Cefotiam has broad-spectrum activity against gram-positive and gram-negative bacterias .Cefotiam has effective in preventing infection following a wide range of urologic surgeries[1][2][3].
Related Catalog
Target

MIC: 1.56 μg/mL (bacterial)

In Vitro Cefotiam (0.78-1.65 ug/mL, 4-8 h) has great antibacterial activity with the MIC value of 1.56 μg/mL against P. mirabilis IFO 3849[1]. Cell Viability Assay[1] Cell Line: P. mirabilis IFO 3849 Concentration: 0.78-1.65 ug / mL Incubation Time: 4-8 h Result: Showed great antibacterial activity
In Vivo Cefotiam (50-200mg/kg; Subcutaneous; twice a day for 5 days) can cure urinary tract infection with P. mirabilis in mice in appropriate doses for a sufficient length of the time[2]. Animal Model: Female CF1/b mice[2] Dosage: 50-200mg/kg Administration: Cefotiam (Subcutaneous; twice a day for 5 days). Result: Treated the experimental urinary tract infections.
References

[1]. Yumi Hashiguchi, et al. Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study. J Infect Chemother. 2020 Nov;26(11):1158-1163.

[2]. T Iwahi, et al. Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice. Antimicrob Agents Chemother

[3]. Kazuhiro Ishizaka, et al. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007 Oct;13(5):324-31.

Density 1.8±0.1 g/cm3
Molecular Formula C18H23N9O4S3
Molecular Weight 525.628
Exact Mass 525.103516
PSA 251.30000
LogP 0.24
Index of Refraction 1.855
Water Solubility Soluble

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XI0366000
CHEMICAL NAME :
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl) amino)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5- yl)thio)methyl)-8-oxo -, (6R-trans)-
CAS REGISTRY NUMBER :
61622-34-2
LAST UPDATED :
199506
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C18-H23-N9-O4-S3
MOLECULAR WEIGHT :
525.68
WISWESSER LINE NOTATION :
T46 ANV ES GUTJ HVQ CMV1- ET5N CSJ BZ& G1S- ET5NNNNJ A2N1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,296,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3840 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,296,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
90 gm/kg/30D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
182 gm/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Skin and Appendages - dermatitis, other (after systemic exposure) Biochemical - Metabolism (Intermediary) - other proteins
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
54600 mg/kg/26W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure) Skin and Appendages - hair
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - changes in adrenal weight
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
30 gm/kg/30D-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 3),163,1979
Hazard Codes Xi